Image
Interactive Exchange

Updates in Systemic Lupus Erythematosus

Unlocking Novel Paths to Patient Care

Meeting Slides

Suggested Readings

European League Against Rheumatism (EULAR) 2020 Annual Meeting Abstracts.

June 3-6, 2020. Virtual.

American College of Rheumatology (ACR) Annual Meeting Abstracts.

November 5-9, 2020. Virtual.

Treat-to-target in systemic lupus erythematosus: recommendations from an international task force.

van Vollenhoven RF, et al. Ann Rheum Dis. 2014;73(6):958-967.

Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial.

Furie RA, et al. Lancet Rheumatol. 2019;1(4):e208-e219.

Trial of anifrolumab in active systemic lupus erythematosus.

Morand EF, et al. N Engl J Med. 2020;382(3):211-221.

Anifrolumab, an anti–interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus.

Furie R, et al. Arthritis Rheumatol. 2017;69(2):376-386.

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.

Furie R, et al. Arthritis Rheum. 2011;63(12):3918-3930.

Two-year, randomized, controlled trial of belimumab in lupus nephritis.

Furie R, et al. N Engl J Med. 2020;383(12):1117-1128.

Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab.

Morand EF, et al. Ann Rheum Dis. 2018;77(5):706-713.

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.

Navarra SV, et al. Lancet. 2011;377(9767):721-731.

AURORA phase 3 study demonstrates voclosporin statistical superiority over standard of care in lupus nephritis.

Arriens C, et al. Ann Rheum Dis. 2020;79(suppl 1):172-173.

B-cell depletion and response in a randomized, controlled trial of obinutuzumab for proliferative lupus nephritis.

Furie R, et al. Lupus Sci Med. 2020;7(suppl 1):A27-A28.

Comprehensive efficacy of anifrolumab across organ domains in patients with active SLE: pooled data from 2 phase 3 trials.

Morand E, et al. Arthritis Rheumatol. 2020;72(suppl 10).

Flare reduction and oral corticosteroid taper in patients with active SLE treated with anifrolumab in 2 phase 3 trials.

Furie R, et al. Arthritis Rheumatol. 2020;72(suppl 10).

Two-year results from a randomized, controlled study of obinutuzumab for proliferative lupus nephritis.

Furie R, et al. Arthritis Rheumatol. 2020;72(suppl 10).

Interactive Presentation

Immunopathogenesis of SLE

This short 3D animation reviews the immunopathogenesis of systemic lupus erythematosus (SLE), relevant disease pathophysiology, and newer targeted therapies.


Activity
Activity for event:Updates in Systemic Lupus Erythematosus

Unlocking Novel Paths to Patient Care

Activity
Activity for event:Updates in Systemic Lupus Erythematosus

Unlocking Novel Paths to Patient Care

Activity
Activity for event:Updates in Systemic Lupus Erythematosus

Unlocking Novel Paths to Patient Care

Relevant Resources

Clinical Updates in Systemic Lupus Erythematosus

Improved Diagnostic and Management Strategies

Advances in Immunosupressive Therapy for Solid Organ Transplantation

Long-Term Management Strategies to Improve Patient Outcomes

Clinical Updates on the Management of Gout

Evidence-Based Strategies for Improved Patient Outcomes

Managing Gout in Primary Care

Evolving Strategies for Diagnosis and Long-Term Management

Improving Outcomes in Rheumatoid Arthritis

Treating to Target, IL-6-Directed Therapies, and Evolving Management Algorithms

Clinical Updates in Rheumatoid Arthritis

Evolving Treatment Algorithms and Expert Perspectives on Biosimilars

Going Deeper on Atopic Dermatitis

Pathophysiology to the Management of Moderate-to-Severe Disease

Looking Beneath The Surface In Atopic Dermatitis

Targeting Immune Dysregulation and Delivering Comprehensive Care

Evolving Treatment Paradigms For Rheumatoid Arthritis

Translating Comprehensive Patient Evaluations Into Personalized Therapy

Clinical Updates in Rheumatoid Arthritis

New Perspectives on Targeting Remission and Individualizing Therapy

A Better Look at Rheumatoid Arthritis

Using Imaging to Improve Patient Outcomes

Clinical Issues in Rheumatoid Arthritis

Discussions and Debates on the Evolving Roles of Targeted Synthetic DMARDs

Pathways to Better Outcomes in Systemic Lupus Erythematosus

Translating Pathophysiology into Targeted Treatments

The Big Picture of IBD

An Interactive Experience Highlighting Recent Clinical Advances

Clinical Issues in Rheumatoid Arthritis

Debates & Discussions on the Evolving Role of JAK Inhibitors

Clinical Issues in Rheumatoid Arthritis

The Evolving Role of JAK Inhibitors

JAKi in RA Practice

Unpacking the Evidence for Their Use Today and Tomorrow

What’s New in Systemic Lupus Erythematosus?

Unlocking Novel Paths to Patient Care

Expert Views on the Changing Landscape in RA

The Increasing Role of JAK Inhibitors

Swimming Upstream in Severe Asthma

New Pathways to Patient Management

Optimizing Advanced Therapies in Ulcerative Colitis: Is Your Practice Up to Date?

A Focus on Clinical Evidence and Guideline Recommendations

Cause for Alarm

New Avenues to the Management of Severe Asthma

Finding the Path in Eosinophilic Esophagitis

Interdisciplinary Strategies for Adult and Pediatric Patients